A Mylan Inc. subsidiary will pay up to $300 million to acquire U.S. commercialization, marketing and IP rights for the anticoagulant Arixtra (fondaparinux) and an authorized generic (AG) of the drug from Aspen Global Inc. in a deal it said will be immediately accretive to adjusted earnings.